On June 23, 2026 Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company focused on central nervous system ("CNS") cancers, reported that management will host a business update conference call and webcast on Tuesday, June 30, 2026, at 8:30 a.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the call, management will focus on the Company’s CNSide diagnostic launch and its integrated development plan for lead drug Reyobiq. Furthermore, management will provide further detail on its CNS oncology strategy and native artificial intelligence development plans.

"Our team is making substantial progress in all 3 areas of the company, specifically diagnostics, therapeutics and artificial intelligence," said Marc H. Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics. "We are excited to provide an update on our progress toward our milestones and vision for the company to enable better outcomes for CNS oncology patients and provide long-term value creation for stockholders."

Conference Call and Webcast Details

Date: Tuesday, June 30, 2026
Time: 8:30 a.m. Eastern Time
Webcast: Link
Dial-in (U.S./Canada): 1-888-349-0106
Dial-in (International): 1-412-317-6789

A replay of the webcast will be available following the event in the Investor Relations section of the Company’s website at www.plustherapeutics.com.

(Press release, Plus Therapeutics, JUN 23, 2026, View Source [SID1234668927])